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Abstract. ARIA, or acetylcholine receptor-inducing 
activity, is a polypeptide that stimulates the synthesis of 
acetylcholine receptors in skeletal muscle. Here we 
demonstrate that the ability of ARIA to induce phos- 
phorylation of its receptor in muscle is blocked by 
highly charged glycosaminoglycans. ARIA constructs 
lacking the NH2-terminal portion, containing an immu- 
noglobulin-like domain, are fully active and are not in- 
hibited by glycosaminoglycans. Limited proteolysis of 
ARIA with subtilisin blocks the glycosaminoglycan in- 
teraction by degrading this NH2-terminal portion, but 
preserves the active, EGF-like domain. We also show 
that ARIA can be released from freshly dissociated 
cells from embryonic chick spinal cord and cerebellum 
by either heparin, high salt or limited proteolysis with 
subtilisin, suggesting that ARIA is bound to the extra- 
cellular matrix through charged interactions. We 
present a model of how ARIA may be stored in extra- 
cellular matrix at developing synapses and how its re- 
lease may be mediated by local proteolysis. 
S 
YNAPSE formation is a complex process bringing to- 
gether elements from the presynaptic neuron and 
postsynaptic cell to form a highly specialized node 
for communication. The molecular architecture at the syn- 
apse may be regulated by polypeptides which serve as first 
messengers in a cascade that activates crucial programs for 
differentiation (see  Hall and  Sanes,  1993 for recent  re- 
view). Acetylcholine receptor-inducing activity (ARIA)  1 
is  a  factor produced by spinal motor neurons that pro- 
motes the synthesis of acetylcholine receptors in embry- 
onic myotubes (Jessell et al.,  1979; Usdin and Fischbach, 
1986; Falls et al., 1993). Other effects of ARIA on muscle 
that mimic effects of motor neuron axons include increas- 
ing the number of voltage-gated sodium channels (Corfas 
and Fischbach, 1993b) and increasing the expression of the 
acetylcholine receptor subunit characteristic of the adult 
acetylcholine receptor (Martinou et al.,  1991). We postu- 
late that ARIA is released from developing motor nerve 
terminals and activates its receptor  on  the postsynaptic 
membrane. Supporting this, ARIA is expressed in embry- 
onic spinal motor neurons  at  the  time of nerve-muscle 
synapse formation (Corfas et al.,  1995).  Also consistent 
with this hypothesis is that ARIA binds to and causes the 
phosphorylation of its receptor (p185) on tyrosine residues 
in primary chick myotubes and the L6 muscle-derived cell 
line (Corfas et al., 1993a). 
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1. Abbreviations  used in this paper.  ARIA, acetylcholine receptor-induc- 
ing activity;  GGF, glial growth factor; NDF, Neu differentiation factor; 
hNDF, human NDF. 
Sequence analysis of ARIA from cloned cDNA suggests 
that the purified 42-kD polypeptide is first expressed as a 
considerably larger transmembrane precursor called pro- 
ARIA (Falls et al., 1993).  Sequence analysis has also re- 
vealed that ARIA is one isoform of a growing family of 
regulatory factors all of which are probably derived from a 
common gene by alternative mRNA splicing (Marchionni 
et al., 1993). Other members of this family include Neu dif- 
ferentiation factor (NDF), heregulin, and glial growth fac- 
tor (for review see Peles and Yarden, 1993). Each of these 
factors was independently purified on the basis of a unique 
biological activity. NDF was purified from the medium of 
ras-transformed rat fibroblasts based on its ability to cause 
tyrosine phosphorylation of the Neu oncogene (Wen et al., 
1992).  It also induces differentiation of mammary tumor 
cells to milk-producing cells. The heregulins are homolo- 
gous human isoforms derived from a human breast tumor 
cell line (Holmes et al., 1992). Glial growth factor (GGF) 
was purified from bovine pituitary on the basis of its mito- 
genic activity in Schwann cells (Goodearl et al., 1993; Mar- 
chionni et  al.,  1993).  Each  of these  factors contains an 
EGF-like domain, which has been shown to be sufficient 
for both  receptor  binding and  phosphorylation of p185 
(Holmes et al., 1992; Wen et al., 1994), and an immunoglo- 
bulin-like domain, of unclear function. Recent experiments 
have suggested that the Neu proto-oncogene may not in 
fact be the true receptor for ARIA and its isoforms, but 
becomes phosphorylated on tyrosine only following bind- 
ing to and hetereodimerization with either one of its ho- 
mologous EGF-like receptors, erbB-3 or erbB-4 (for re- 
view see Carraway and Cantley, 1994). 
One feature of chicken brain ARIA that enabled its pu- 
rification was its ability to bind to heparin columns (Falls 
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cosaminoglycans in the extracellular matrix may be impor- 
tant in regulating ARIA's actions. There  are  a  growing 
number of examples of polypeptide growth and differenti- 
ation factors that bind to extracellular matrix proteogly- 
cans.  These  include  acidic  and  basic  fibroblast  growth 
factors,  transforming growth  factor-[~,  granulocyte-mac- 
rophage  colony-stimulating  factor,  interleukin-3,  inter- 
feron % the netrins, and neurotrophin-6  (Ruoslahti and 
Yamaguchi, 1991; Gotz et al.,  1994; Serafini et al.,  1994). 
Interactions with extracellular matrix are thought to pro- 
vide a readily accessible store of factors, to protect them 
from degradation, and in some instances, enhance their bi- 
ological activities. Release of bound factors from extracel- 
lular matrix can be achieved by proteolysis of the core pro- 
teoglycan or by local release of heparin (Hardingham and 
Fosang, 1992). 
An attractive hypothesis is that ARIA may be concen- 
trated  at  synapses through binding to  heparin-like  gly- 
cosaminoglycans in  the  extracellular matrix.  Along  this 
line,  in  vivo  studies  have  suggested  that  after  axonal 
transection, neuromuscular basal lamina retains an activity 
which  promotes  the  synthesis  of acetylcholine receptor 
subunits (Goldman et al., 1991; Jo and Burden, 1992). Fur- 
thermore, ARIA (neuregulin) immunoreactivity has been 
localized to the neuromuscular synapse and remains asso- 
ciated with basal lamina in the absence of nerve and mus- 
cle (Jo et al., 1995). 
In this paper we have localized the heparin-binding por- 
tion of ARIA to its NH2 terminus containing an immuno- 
globulin-like domain. We find that both limited proteoly- 
sis with subtilisin or heparin treatment can release ARIA 
from the  extracellular matrix of chick embryonic spinal 
cord and cerebellum.  We present evidence that this re- 
lease can be achieved through proteolytic inactivation of 
the  heparin-binding  domain resulting in  a  partially de- 
graded form of ARIA which is soluble and active. Unlike 
other growth factors whose activity is potentiated by hep- 
arin, we find that heparin blocks ARIA-induced receptor 
phosphorylation. 
Materials and Methods 
ARIA Forms 
Recombinant ARIA was purified from the media of transfected COS-7 
cells. Cells were transfected as described previously (Fall et al., 1993) with 
a construct of the k12 clone to which an NH2-terminal FLAG epitope was 
added and inserted into the Barn H1 site of the vector pcDNA I/AMP (In- 
vitrogen, San Diego, CA). This was accomplished by first introducing a 
48-nucleotide oligonucleotide encoding the flag epitope into the BstX1 
site. The resultant NHz-terminal predicted amino acid sequence for this 
construct is MGDYKDDDDKGPVCWNSGVLRGM, where the last me- 
thionine residue corresponds to the first amino acid of the k12 insert. Op- 
tiMEM I media (GIBCO BRL, Gaithersburg, MD) was harvested 3 d af- 
ter  transfection  and  applied  to  a  0.5-ml  column  of  anti-FLAG  (M2) 
antibody-coupled agarose (International Biotechnologies, Inc., New Ha- 
ven, CT) and eluted with 0.1 M  glyeine (2.5). The fractions were rapidly 
neutralized with 0.1 vol of I  M Tris-HC1 (8.0).  Fractions with phosphory- 
lation activity were pooled and applied to an Altex C4 reverse phase col- 
umn in 0.1% trifluoroacetic acid. It was eluted on a 0-60% gradient of ace- 
tonitrile and came off as a single peak. This material was stored at 4°C and 
dried down before use. Constructs of the human forms of ARIA were 
generously provided by AMGEN  (Thousand Oaks,  CA).  The isolated 
EGF-like domain corresponds to amino acids 177-246 of the human 131 
form  expressed in  Escherichia  coll.  The  Ig-EGF  form  corresponds to 
amino acids 14-246 of the human 131 form expressed also in E. coli. 
Glycosaminoglycan Inhibition of  ARIA-induced 
Receptor Phosphorylation 
Various preparations of recombinant ARIA were diluted into 150 pJ of 
L6 media (DME  containing 10%  heat-inactivated fetal calf serum, 1% 
glutamine, and 1%  penicillin/streptomycin, all purchased from GIBCO 
BRL). Stock solutions of glycosaminoglyeans  were added to give the final 
indicated concentrations and incubated at room temperature with various 
forms of ARIA for 5 min before addition to L6 muscle cells, p185 phos- 
phorylation on tyrosine residues was performed as described previously 
(Corfas et al.,  1993a).  Essentially, samples were  applied  to  ceils plated 
6-10 d  previously at a  density of 50,000 cells per well of a 48-well tissue 
culture dish. After 30--45 min of treatment, the media was discarded, the 
cells solubilized in 2x SDS sample buffer, and boiled for 5 min. Phospho- 
tyrosine on p185  was detected  by Western blot  analysis using a  mono- 
clonal antibody directed against phosphotyrosine (mAb 4G10 generously 
provided by B. Druker and T. Roberts, Dana Farber Cancer Center, Bos- 
ton, MA) after resolution on overrun 5% reducing SDS-polyacrylamide 
gels. The filters were then probed with a goat anti-mouse IgG coupled to 
peroxidase (Boehringer Mannheim Corp., Indianpolis, IN)  and exposed 
to film after treatment with chemiluminescence reagents (Dupont-NEN, 
Boston, MA). Heparin (porcine intestinal mueosa, ~13,000 Mr), heparan 
sulfate, dextran sulfate, dermatan sulfate, keratan sulfate were purchased 
from Sigma Chemical Co.  (St.  Louis, MO).  Chondroitin sulfate (chon- 
droitin sulfate A) was from Boehringer Mannheim. 
HPLC Gel Filtration of  Proteolytic Fragments 
An equal amount of COS-expressed ARIA was treated without and with 
50 ~Lg/ml  of subtilisin at room temperature for 20 min. The reaction was 
stopped with the addition of PMSF at a final concentration of i  p,g/ml. 100 
I~l of each was loaded in series onto the same Altex TSK 3000 (0.75  x  30 
mm) gel filtration HPLC column preequilibrated with 30%  acetonitrile, 
0.1% trifluoroacetic acid, flowing at 0.4 ml/min, 0.4-ml fractions were col- 
lected and 0.2 ml of each were then lyophilized, reconstituted in L6 media, 
and assayed for p185 phosphorylation activity. Densitometry of films us- 
ing a computing densitometer (model 300B; Molecular Dynamics, Sunny- 
vale, CA) was used to quantify the amount of activity in each fraction. The 
total activity was normalized to 100% and plotted as percent of total. Ac- 
tivity from chick cerebellum was obtained by treating 10 million freshly 
isolated cerebellum cells, isolated as described below, with 10 ~Lg/ml of 
subtilisin (Boehringer Mannheim) in PBS, 1 mM CaC12 for 20 min at room 
temperature. The ceils were spun down at 14,000  rpm in an Eppendorf 
centrifuge and the 100-1xl  supernatant was removed, made 1 mg/ml PMSF, 
and immediately applied to the same HPLC gel filtration column run ex- 
actly  as above. Fractions were  assayed and quantified as above.  Using 
identical running conditions the following size standards were  used for 
column calibration: carbonic anhydrase (29,000 D), cytochrome C (12,400 
D), and aprotinin (6,500 D)  (Sigma). The elution positions of standards 
were measured at OD280 and confirmed by SDS-polyacrylamide gel elec- 
trophoresis followed by staining with coomassie brilliant blue. 
Nonenzymatic Preparation of Cells  from Chick 
Embryonic Cerebellum  and Spinal Cord 
Whole cerebellum or spinal cord were removed from El7 chick embryos 
and placed  on ice  in  Hank's balanced salt solution containing 10  mM 
Hepes, pH 7.4 (HBSS/7.4; GIBCO BRL). The meninges  were carefully re- 
moved and the tissue transferred to a  tube containing the above buffer 
with  1%  bovine serum albumin (RIA grade;  Sigma) and 500 U/ml of 
DNAseI (Sigma) at room temperature. The tissue was gently triturated 12 
times through a blue pl000 pipette tip. The tissue still remaining was re- 
moved by I min centrifugation at 500 rpm in an IEC HNSII clinical centri- 
fuge. The supernatant was transferred to a new tube containing 10 ml of 
cold HBSS/7.4 and spun for 7 min at 1,200  rpm in the same centrifuge. 
Cells were resuspended in cold PBS, pH 7.4 (GIBCO BRL) and counted. 
This method gives a  high yield of mostly single cells with a  viability of 
~50-60% by trypan blue exclusion. 
Subtilisin- and Heparin-induced Release of Cell 
Surface ARIA 
Five million cells isolated  as described  above were  used for each data 
point. Aliquots of cells were spun at 5,000 rpm for 5 min at 4°C in an Ep- 
pendorf centrifuge and resuspended in 45 I~1 of PBS, pH 7.4,  sometimes 
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fold final concentration of either freshly prepared  subtilisin or heparin 
was added, mixed by vortexing, and incubated for either 20 min at room 
temperature (subtilisin) or at 4°C (heparin). The cells were mixed inter- 
mittently. After 20 min the cells were spun at 14,000 rpm in the same cen- 
trifuge at 4°(2 for 5 min. For analysis of ARIA activity in the supernatants, 
the entire supernatant was added to 100 p,1 of ].,6 media, mixed and added 
to L6 cells for assay of receptor phosphorylation as described above. To 
measure acetylcholine receptor insertion rate, 100 ILl of this released ma- 
terial was diluted ninefold with chick muscle culture media and added to 
primary chick myotube cultures as described previously (Falls, 1993). For 
some experiments the cells were first treated with heparin, centrifuged at 
5,000 rpm in the Eppendorf centrifuge, and then resuspended in 50 i~1 of 
PBS, pH 7.4 containing 1 mM CaC12 and subtilisin to examine the amount 
of activity remaining after heparin treatment. A polyclonal antisera made 
against amino acids 14-241 of an E. coil-expressed human NDF ct2 form 
generously provided by AMGEN (no. 1915) was used to block activity re- 
leased from cerebellum cells. 
Western blots of released activity by heparin, subtilisin, or 1 M  NaC1 
were all performed by resuspending a pellet of five million ceils with 25 ~1 
of the indicated solution incubating as above for 20 min at room tempera- 
ture. The ceils were centrifuged and the supernatants were added to 20 ixl 
of 2× sample buffer, boiled for 5 rain and then analyzed on 10% reducing 
SDS-polyacrylamide gels by Western blot using an affinity purified anti- 
sera generated against a synthetic peptide consisting of the first 27 amino 
acids of chicken ARIA (HM21). The blots were developed using a goat 
anti-mouse IgG linked to peroxidase and chemiluminescence  as described 
above.  Densitometry of the Western blots was performed as described 
above. 
Results 
ARIA Contains a Heparin-binding 
Domain Which When Bound to Heparin Blocks 
Receptor Phosphorylation 
One  key feature that  enabled the purification of ARIA 
from chicken brain was that ARIA could bind tightly to a 
heparin column, requiring 0.45-0.65 M  NaC1 to elute the 
activity (Falls et al., 1993). Since heparan sulfate is present 
in the synaptic basal lamina of neuromuscular junctions, 
we were interested in characterizing the role of heparin on 
ARIA's actions (Sanes et al., 1986). Heparin was added to 
recombinant chicken ARIA before the addition of both to 
cultured  L6  muscle  cells.  Receptor  interaction  was  as- 
sessed by measuring the extent of p185 tyrosine phosphor- 
ylation using Western blot analysis. At 500 p~g/ml, heparin 
blocks nearly all of the p185 phosphorylation (Fig. 1). The 
half maximal blocking concentration of heparin is ~5 vLg/ 
ml  or  40  nM.  When  the  same  concentrations  of chon- 
droitin sulfate are added to ARIA, there is no inhibition 
of phosphorylation. Thus, heparin, in addition to binding 
to ARIA, blocks its ability to induce phosphorylation of 
its receptor. 
To  determine  which  portion  of ARIA  interacts  with 
heparin, various constructs were examined for their ability 
to induce receptor phosphorylation in the presence of gly- 
cosaminoglycans. Fig. 2 summarizes the predicted domain 
structure of proARIA along with three constructs used for 
these studies. Both chicken ARIA and human NDF (hNDF) 
constructs were used, since no differences in biological ac- 
tivity have thus  far been detected between these forms. 
Two of the constructs, ARIA and hNDF-13114_246  contain a 
[31 EGF-like domain connected by a variable length serine/ 
threonine-rich spacer to an immunoglobulin-like domain. 
The third construct was hNDF-~31177.246, which has only a 
[31 EGF-like domain. 
Figure 1.  Heparin blocks ARIA-induced receptor phosphoryla- 
tion in cultured L6 muscle cells. Recombinant ARIA was incu- 
bated in L6 media with the indicated final concentrations of hep- 
arin  or  chondroitin  sulfate  and  added  to  confluent  L6  cell 
cultures  for 30 min. The cells were solubilized in SDS sample 
buffer and p185 phosphorylation  activity (arrows) was measured 
by Western blot analysis using anti-phosphotyrosine  antibodies. 
hNDF-[M14_246-induced  receptor phosphorylation is blocked 
by heparin at a half-maximal concentration which is simi- 
lar to that observed with ARIA (Fig. 3 a). In contrast, hep- 
arin does not block the phosphorylation activity of hNDF- 
[31177.246 that  consists  of only the  EGF-like  domain.  No 
decrease is observed even at the highest heparin concen- 
trations.  Consistent  with  this,  hNDF-[~1177.246 does  not 
bind to heparin-linked agarose as  do all constructs con- 
taining the immunoglobulin-like domain (data not shown). 
These results suggest that heparin binds to the NH2-termi- 
nal portion of ARIA, containing the immunoglobulin-like 
domain, and prevents the association of the EGF-like do- 
main with its receptor. To explore the specificity of this 
glycosaminoglycan  interaction,  various  glycosaminogly- 
cans,  differing  in  charge  density,  were  then  added  to 
hNDF-[3114.246. While heparin, heparan sulfate, dermatan 
sulfate, and dextran sulfate block p185 phosphorylation in- 
duced by hNDF-~lla.z46, keratan sulfate and chondroitin 
sulfate, which are less negatively charged, have no effect 
(Fig. 3 b). 
Limited Proteolysis of  ARIA Restores Activity in the 
Presence of  Heparin 
The  presence  of  a  heparin-binding  domain  specifies  a 
means by which ARIA could bind to negatively charged 
molecules  such  as  glycosaminoglycans  on  extracellular 
matrix proteoglycans. Once bound, however, ARIA is un- 
able to induce receptor phosphorylation. Since the EGF- 
like domain alone is sufficient for biological activity, one 
way to avoid this inhibition by glycosaminoglycans is to re- 
move or inactivate the heparin-binding domain while pre- 
serving the function of the EGF-like domain. We found 
that we could accomplish this by using limited proteolysis 
with the nonspecific protease, subtilisin. Fig. 4 shows that 
while heparin completely blocks p185 phosphorylation in- 
duced by hNDF-•114.246,  after limited proteolysis with sub- 
tilisin, heparin no longer blocks phosphorylation of p185. 
This result suggests that the heparin-binding activity can in 
fact be dissociated from the receptor phosphorylation ac- 
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ture and constructs. ProARIA 
has  an NH2-terminal  immu- 
noglobulin-like  domain (Ig), 
an EGF-like domain (EGF), 
a  putative  transmembrane 
sequence  (TM), and  a  large 
COOH-terminal  domain. 
Cleavage  occurs  somewhere 
between  the  EGF-like  do- 
main and the transmembrane 
domain to produce a soluble 
polypeptide  containing  both 
the  immunoglobulin  and 
EGF-like  domains.  Con- 
structs used in these studies include chicken ARIA and human hNDF-[314_246,  each containing both the immunoglobulin-like domain and 
the EGF-like domain and hNDF-~177.246  that consists of an isolated EGF-like domain. 
tivity by proteolysis. Subtilisin  treatment  also reduces the 
total amount of activity perhaps due to partial degradation 
of the EGF-like domain. 
The  size of active fragments  produced by limited  pro- 
teolysis of recombinant  ARIA  with  subtilisin  was exam- 
ined by HPLC gel filtration chromatography. Before treat- 
ment  with  subtilisin,  ARIA  has  an  apparent  molecular 
mass  of 25 kD  (Fig.  5).  This  same  glycoprotein migrates 
with  an  apparent  molecular  mass  of 42  kD  on  reducing 
SDS-polyacrylamide gels. After brief treatment with sub- 
tilisin  and  application  to  the  same  column,  the  receptor 
phosphorylating activity now elutes as two lower molecu- 
lar mass peaks of 11.5 and 5.3 kD. The 5.3-kD activity is 
consistent in size with  an isolated EGF-like domain. The 
ll.5-kD  activity  likely  contains  the  EGF-like  domain, 
since  it  is  active,  with  varying portions  of the  degraded 
NH2 terminus. 
Thus limited proteolysis effectively inactivates the hep- 
arin-binding  activity by removing part  or all  of the  NHz 
terminus containing the immunoglobulin-like domain while 
preserving the function of the EGF-like domain, which is 
relatively resistant to proteolysis. This relative susceptibil- 
ity  to  proteolysis  may  be  an  important  mechanism  em- 
ployed for releasing  ARIA from the extracellular  matrix 
in vivo. 
ARIA Can Be Released from Embryonic Chick Spinal 
Cord and Cerebellum 
In light  of the  above  findings,  we asked  whether  ARIA 
Figure 3.  The NH2 terminus of ARIA is a selective  glycosami- 
noglycan binding domain. (a) hNDF-1314.246 (Ig-EGF) or hNDF- 
~177-246 (EGF) at 100 pM each were mixed with increasing con- 
centrations of heparin and applied to L6 cells  to measure p185 
phosphorylation as in Fig.  2. (b)  100 pM hNDF-131,246 Ig-EGF, 
was mixed with 500 ~g/ml of the indicated glycosaminoglycans or 
dextran sulfate and analyzed for p185 phosphorylation activity in 
L6 cells. 
Figure 4.  Heparin no longer 
blocks receptor phosphoryla- 
tion after limited proteolysis 
of ARIA. hNDF-[~14.246, con- 
taining both the immunoglo- 
bulin and EGF-like domains 
(100 pM final concentration) 
was digested with 0.1  v.g/ml 
subtilisin  in  PBS,  1  mM 
CaC12 for  20  min  at  room 
temperature.  The  reaction 
was stopped by the addition 
of L6 media. Both digested and nondigested hNDF-1314.246 were 
mixed with or without 200  ixg/ml of heparin before addition to 
the L6 cells to assess p185 receptor phosphorylation, 
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Figure 5.  HPLC gel filtration analysis of ARIA after limited pro- 
teolysis  with  subtilisin  reveals two peaks of activity  coinciding 
with activity released from chick cerebellum.  ARIA (11), subtili- 
sin-treated ARIA (e), and activity released by subtilisin  treat- 
ment of freshly isolated cerebellum cells (A) were analyzed  se- 
quentially  on the same HPLC gel filtration column.  The p185 
phosphorylation activity was assayed in each fraction and nor- 
malized as the percentage of total activity per sample. The elu- 
tion profiles are plotted on the same chart for comparison.  29, 
12.4, and 6,5 refer to the elution positions in kD of the molecular 
weight standards carbonic anhydrase, cytochrome C, and aproti- 
nin, respectively. 
could be released from the surface of freshly isolated chick 
central nervous tissue cells by limited proteolysis. Spinal 
cord and cerebellum were used since in situ hybridization 
analysis has demonstrated high levels of ARIA mRNA ex- 
pression both in spinal motor neurons and in the cerebel- 
lum (Corfas et al., 1995). Cells from embryonic day 17 spi- 
nal cord and cerebellum were isolated without protease so 
as to preserve the extracellular proteins and treated briefly 
with  subtilisin.  After  centrifugation  to  remove the  cells, 
the activity released was assayed by measuring the extent 
of p185 tyrosine phosphorylation in L6 muscle cells. Fig. 6 
a shows that subtilisin treatment releases p185 phosphory- 
lation activity from both spinal cord and cerebellum cells. 
Other proteases including trypsin, chymotrypsin, V8, and 
elastase also release this activity, suggesting that this effect 
is not unique to subtilisin (data not shown). Thus far, we 
have found no other factors that induce the phosphoryla- 
tion of this 185-kD protein in L6 muscle ceils and thus be- 
lieve  this  released  material  to  be  ARIA  (Corfas  et  al., 
1993a). 
There  are  four  additional  features  of this  activity re- 
leased by subtilisin  that  suggest that it is indeed  ARIA. 
Experiments for these studies were performed using cere- 
bellum cells because of a  greater amount of ARIA pre- 
sent.  First,  antibodies  directed  against hNDF, but which 
recognize  recombinant  chicken ARIA on Western blots 
and immunoprecipitations are able to block the released 
activity by N40% (Fig. 6 a). Even with other antibodies di- 
rected against various forms of ARIA, only partial block- 
age of the released activity could be achieved perhaps due 
to  a  lowered affinity of the  antibodies  to the  proteolyti- 
cally degraded ARIA. Second, the activity released from 
cerebellum increases the insertion rate of acetylcholine re- 
ceptors in primary chick myotube cultures  by 1.6  ___  0.1- 
Figure  6.  ARIA can be re- 
leased  from  chick  spinal 
cord and cerebellum.  (a) Five 
million nonenzymatically  iso- 
lated  ceils  from  El7  chick 
spinal  cord  and  cerebellum 
were incubated for 20 rain at 
room temperature in 50 ~1 of 
PBS, 1 mM CaC12  with 10 ~g/ 
ml of subtilisin. 100 pJ of L6 
media was added to the  su- 
pernatant  of each and  p185 
phosphorylation activity was 
measured  by  Western  blot 
analysis.  Antisera  to  ARIA 
was added to one of the sub- 
tilisin  treated  samples  20 
rain  before  addition  to  L6 
cells for p185 analysis at a fi- 
nal dilution  of 1:10. (b) Five 
million cells from cerebellum 
were incubated for 20 min at 
room  temperature  with  ei- 
ther 25  ixl of PBS  alone,  or 
with  subtilisin  (10  ixg/ml), 
heparin (200 ~g/ml).  or 1 M 
NaCl.  A  Western  blot  was 
performed  on  the  released 
material  using  an  affinity- 
purified,  anti-peptide  anti- 
sera directed against the first 
27  NH2-terminal  amino  ac- 
ids of chicken ARIA. 
fold over nonstimulated cultures  (quadruplicate  samples, 
as described in Materials and Methods). 
Third, when the activity released by subtilisin from cere- 
bellum cells is analyzed by HPLC gel filtration chromatog- 
raphy, two peaks of activity elute at 12 and 4.8 kD (Fig. 5). 
These fragments match the size of the fragments produced 
by  subtilisin-cleavage  of recombinant  chicken  ARIA  at 
11.5  and 5.3  kD. The similarity in size and pattern of the 
subtilisin-cleaved recombinant ARIA and the cerebellum- 
released  activity  suggests  that  they  are  derived  from  a 
common  protein  backbone,  and,  indeed  represent  frag- 
ments of ARIA released from these cells lacking portions 
of their NH2 termini. 
Finally, Fig. 6 b shows that on Western blot, two bands 
of 42 and 45 kD are released from freshly dissociated cere- 
bellum cells.  This Western  blot uses  an  affinity-purified 
polyclonal antisera made against the first 27 NH2-terminal 
amino acids of ARIA (HM21). This antisera specifically 
recognizes  recombinant  forms  of  ARIA  expressed  in 
COS-7 cells on Western blots (data not shown). Following 
treatment  of the  cells with subtilisin,  these  bands  disap- 
pear, which would be expected if the NH  2 terminus were 
degraded. However, when heparin or 1 M  NaC1 is added 
the amount of these two proteins increases by 1.9- and 2.4- 
fold,  respectively  (data  obtained  by  densitometry).  The 
observation  that  immunoreactive  proteins  consistent  in 
size with ARIA are also releasable by heparin or high salt 
further supports the hypothesis that ARIA may be associ- 
ated with the  extracellular matrix of these  cells through 
ionic interactions. 
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Extracellular Matrix 
The observation that ARIA can be released from the sur- 
face of cerebellum cells by heparin, high salt, and limited 
proteolysis, suggests that ARIA is associated with the ex- 
tracellular matrix of these cells. To assess the proportion 
of ARIA that  is matrix bound,  we  attempted to release 
ARIA  from cerebellum  cells  by treatment  with  various 
concentrations  of heparin.  While  detectable  p185  phos- 
phorylation activity is released from these cells at low con- 
centrations  of  heparin  (10  Ixg/ml),  high  concentrations 
(100 ixg/ml) yield less detectable activity (Fig. 7 a). This is 
not  unexpected  because  high  concentrations  of heparin 
also  block  ARIA-induced  p185  phosphorylation.  In  the 
same experiment, chondroitin sulfate at 10 ixg/ml does not 
release any activity, again demonstrating the specificity of 
the interaction. 
To avoid this  limitation,  we  measured  the  activity re- 
maining  after  treatment  of  cerebellum  cells  with  in- 
creasing  concentrations  of  heparin.  Following  heparin 
treatment, the cells were washed to remove the heparin to- 
gether with the ARIA released by the heparin. They were 
then resuspended with subtilisin to measure the remaining 
cell associated activity. Fig. 7 b shows that high concentra- 
tions of heparin (200 ~g/ml) remove over 60% of the sub- 
tilisin-releasable activity. It also shows that neither 50 txg/ 
ml  of  chondroitin  sulfate  nor  pretreatment  with  0.1% 
Triton X-100,  a  nonionic detergent, releases ARIA. The 
observation that a nonionic detergent does not release the 
activity is  consistent  with  heparin  causing a  specific dis- 
ruption  of ionic  interactions  which  attach  ARIA  to  the 
surface  of  these  cells,  such  as  binding  to  heparin-like 
glycosaminoglycans expressed on extracellular matrix pro- 
teoglycans. 
Figure 7.  Release of ARIA from cerebellum cells with heparin. 
(a) 5 million chick cerebellum cells were washed and treated with 
0, 10, or 100 p,g/ml of heparin or 10 p,g/ml of chondroitin  sulfate 
(CS) in 50 txl PBS for 20 min on ice. The cells were removed by 
centrifugation  and the ARIA present in the supernatant was as- 
sayed for p185 phosphorylation activity by Western blot analysis. 
(b) Cells were treated as in (a) for 20 min in PBS containing  ei- 
ther 0--200 p~g/ml heparin, 50 p~g/ml chondroitin  sulfate, or 0.1% 
Triton X-100. After centrifugation  to remove the cells, the super- 
natants were removed and the cell pellets were resuspended in 50 
pA of 10 ~g/ml of subtilisin  in PBS,  1 mM CaC12 for 20 min at 
room temperature. Following the reaction, the samples were cen- 
trifuged  and the supernatants were assayed  for p185 phosphor- 
ylation activity. 
While most of the cell surface ARIA is released by high 
concentrations of heparin, there seems to be a  small pro- 
portion of ARIA that is not releasable by heparin (Fig. 7 
b). This could be due to a different type of cell surface in- 
teraction that is not disrupted by heparin or to the  pres- 
ence of a  transmembrane form that  requires  proteolysis 
for release. 
Discussion 
ARIA Has Distinct Domains for Heparin-binding and 
Acetylcholine Receptor-including Activity 
Our results have shown that, when the EGF-like domain 
of ARIA is linked to the NH2-terminal portion including 
the  immunoglobulin-like  domain,  phosphorylation of its 
receptor, p185, is blocked by heparin. This inhibition is se- 
lective  for  more  negatively charged  glycosaminoglycans 
such as heparin, heparan sulfate and dermatan sulfate, and 
dextran sulfate. Other less highly charged glycosaminogly- 
cans such as ehondroitin sulfate and keratan sulfate do not 
block activity. In contrast, the isolated EGF-like domain is 
fully active in the presence of heparin. These results sug- 
gest that heparin binds to the NHz terminus of ARIA con- 
taining  the  immunoglobulin-like  domain  and  somehow 
prevents a  successful interaction of the EGF-like domain 
with its receptor. 
We  suspect that  the  heparin  binding site  is within  the 
immunoglobulin-like  domain  of chicken  ARIA because 
this is the only region of the protein that contains a partic- 
ularly high density of positively charged residues  (13 out 
of 56 amino acids between the two conserved cysteines). 
This  might  produce  a  tight  interaction  with  negatively 
charged glycosaminoglycans. One portion of this sequence, 
amino  acid  numbers  70-75  (TKKNRP),  conforms  to  a 
consensus  sequence  for  heparin  binding  found  in  vit- 
ronectin, apolipoproteins E  and B-100, and platelet factor 
4  (Cardin  and  Weintraub,  1989).  This  corresponds  to  a 
motif [X-B-B-X-B-X], where B is a basic residue and X  is 
a hydropathic residue. Mammalian forms of ARIA (NDF 
or heregulins)  have an  additional,  positively charged se- 
quence on their NH/terminus in addition to the one found 
in their immunoglobulin-like domains. Half of the residues 
in  the  amino  acids  between  4-23  are  positively charged 
(Holmes et al., 1992).  However, the particular human con- 
struct we used, hNDF-I3114_z46, lacks the first half of this se- 
quence, but is still effectively blocked by heparin. 
Early efforts in the purification of ARIA demonstrated 
two peaks of activity at high and low molecular mass (Jes- 
sell et al., 1979).  Later purification efforts, which included 
more protease inhibitors, identified only the high molecu- 
lar mass 42-kD form (Usdin and Fischbach, 1986).  We de- 
scribe experiments here showing that while the immuno- 
globulin-like domain is quite sensitive to proteolysis, the 
EGF-like  domain  is  relatively  resistant  and  can  be  ob- 
served as a low molecular mass peak on gel filtration chro- 
matography.  One  hypothesis  now raised  is  that  the  low 
molecular mass form previously purified  corresponds  to 
an  isolated  EGF-like  domain,  generated  by proteolysis. 
Although the EGF-like domain is sufficient for full activ- 
ity, the NH2-terminal portion containing the heparin-bind- 
ing activity could modulate activity by localizing ARIA in 
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needed. 
The best studied system where heparin modulates the 
interaction between a receptor and its ligand activation is 
that  of the FGF family of growth factors (Mason,  1994; 
Ruoslahti  and Yamaguchi,  1991). Heparin, although not 
required for receptor activation, increases the affinity of 
FGF for its receptor perhaps by bridging FGF to its recep- 
tor (Mason, 1994; Roghani et al., 1994).  In contrast, hep- 
arin inhibits ARIA-induced receptor phosphorylation. 
ARIA Can Be Released from the Extracellular Matrix 
In addition to binding heparin in vitro we also now pro- 
vide evidence that ARIA may use this ability in vivo to ac- 
cumulate in extracellular spaces in the central nervous sys- 
tem. ARIA can be released from freshly dissociated cells 
from chick embryonic central nervous system by either 
proteolysis,  heparin,  or  high  salt.  Similar  observations 
have been made on a  heparin-binding protein mitogenic 
for Schwann cells, which may belong to the ARIA/GGF/ 
NDF family (Rather et al., 1988). This activity could be re- 
leased from the surface of rat dorsal root ganglia cells and 
blocked by low concentrations of heparin (1 }xg/ml). 
Release of other factors thought to associate with pro- 
teoglycans in the extracellular matrix have been achieved 
similarly.  Heparin-binding  growth  factors  such  as  basic 
and acidic FGF, granulocyte-macrophage colony-stimulat- 
ing factor, interleukin 3, and interferon gamma bind to the 
glycosaminoglycan portion of proteoglycans (Hardingham 
and Fosang,  1992), whereas  other factors such  as  trans- 
forming growth factor-J3,  and  leukemia inhibitory factor 
(cholinergic differentiation factor) bind to the polypeptide 
portion (Ruoslahti  and Yamaguchi,  1991;  Mereau et al., 
1993). The heparin-binding growth factors have also been 
shown to be released from extracellular matrix by compe- 
tition with soluble heparin or degradation of the matrix 
proteoglycans with protease. These two modes of releas- 
ing factors are thought to occur at sites of inflammation, 
by the secretion of heparin by mast cells, and in extracellu- 
lar matrix remodelling, by extracellular protease activities. 
We favor a novel, proteolytic mechanism for the release of 
ARIA  from the extracellular matrix that  dissociates the 
heparin binding activity from the biologically active EGF- 
like domain. 
The  identity  of  the  extracellular  protein  that  binds 
ARIA in the central nervous system is unknown. This pro- 
tein could either be a component of the extracellular ma- 
trix  or  the  extracellular  portion  of a  membrane-bound 
protein. In the peripheral nervous system, agrin, a protein 
known to cause clustering of acetylcholine receptors, binds 
to  heparin  and  is  localized in  synaptic basement  mem- 
branes (for review see Nastuk and Fallon, 1993). Recently, 
dystroglycan, a  muscle cell proteoglycan associated with 
the dystrophin-associated glycoprotein complex, has been 
shown to bind to agrin (Bowe et al., 1994; Campanelli et 
al.,  1994; Gee et al., 1994; Sugiyama et al.,  1994). This in- 
teraction also can be blocked with heparin. Heparin inhib- 
its agrin-induced receptor clustering on myotube cultures 
and neuromuscular synapse formation in Xenopus nerve- 
muscle cocultures (Wallace, 1990; Saito et al., 1993). While 
the  specific  extraceUular  matrix  binding  molecule  for 
ARIA at the neuromuscular junction is also unknown, any 
extracellular matrix proteoglycan expressing highly charged 
glycosaminoglycans,  or  for  that  matter,  any  negatively 
charged surface protein is a potential binding site. 
A Model for the Storage and Release of  ARIA at 
Synaptic Junctions 
We postulate that ARIA derived from a presynaptic mo- 
tor  neuron  leads  to  differentiation  of  the  postsynaptic 
muscle  cell  at  developing  synapses  (Falls  et  al.,  1990). 
Most  of our work thus  far has  centered on the  role  of 
ARIA in the development of the neuromuscular junction, 
but ARIA's presence in all cholinergic neurons in the cen- 
tral nervous system as well as noncholinergic neurons in 
both the cortex and the cerebellum suggests that it may 
also  be  a  potent differentiation factor in  these  areas  as 
well. Our observation here that ARIA is present and re- 
leasable from extracellular binding sites in the chick spinal 
cord and cerebellum by either subtilisin  or heparin sug- 
gests that extracellular reservoirs of ARIA may be present 
in synaptic junctions and that its release could be mediated 
by local protease activity. One possible mechanism that in- 
corporates these observations is presented in Fig. 8. In this 
model, ARIA is concentrated in the synaptic cleft by bind- 
ing to negatively charged molecules, such as proteoglycans 
in the extracellular matrix. To get to its receptor on the 
postsynaptic cell, ARIA must first be released from the 
matrix by proteolytic cleavage of its heparin-binding do- 
main, thus releasing the active EGF-like domain. This pro- 
cess could be regulated by a balance between protease ac- 
tivities and protease inhibitors in the extraceUular matrix. 
One intriguing possibility is that during synaptogenesis, a 
Figure 8.  A model for protease-mediated release of ARIA from 
extracellular matrix. ARIA is secreted by neurons into the extra- 
cellular space. Once released,  the immunoglobulin-like  domain 
(IG) may bind to the glycosaminoglycan portion of proteoglycans 
in extracellular  matrix (ECM) through ionic interactions.  Once 
bound,  it remains  stored there until it is released by an extra- 
cellular  protease  which  preferentially degrades  the  immuno- 
globulin-like domain thus releasing the active, relatively protease 
resistant, EGF-like domain (EGF). This allows the now soluble 
EGF-like domain to bind to its postsynaptic receptor resulting in 
differentiation of the postsynaptic cell 
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developmentally specific signal for the release of ARIA. 
Support for this model comes from several other lines of 
evidence. Both the central and peripheral nervous system 
contain extracellular proteoglycans  containing glycosami- 
noglycans that could potentially bind ARIA (Sanes, 1989). 
Specifically,  at  neuromuscular  junctions,  antibodies  di- 
rected against heparan sulfate stain the synaptic basal lam- 
ina  (Sanes  et  al.,  1986).  Recently  basal  lamina  prepara- 
tions  lacking  both  nerve  and  muscle  stain  for  ARIA 
immunoreactivity  (Jo et al.,  1995).  We have  recently ob- 
tained both light and EM immunocytochemical  evidence 
that ARIA accumulates in the synaptic cleft at neuromus- 
cular synapses  (Sandrock,  A. W., Jr., A. D. J.  Goodearl, 
Q.  Yin,  D.  Chang,  and  G.  D.  Fischbach.  1995.  ARIA  is 
concentrated  in  nerve  terminals  at  neuromuscular  junc- 
tions and other synapses. J. Neurosci. In press., Goodearl, 
A. D. J., A. G. Yee, A. W. Sandrock, Jr., G. Corfas, and 
G. D. Fischbach.  1995. Submitted.). There is also indirect 
evidence that suggests that an ARIA-like activity is bound to 
the extracellular matrix of neurons. After axotomy, an ac- 
tivity found to increase local transcription of acetylcholine 
receptor subunits remains associated in the basal lamina of 
neuromuscular  junctions  (Goldman  et  al.,  1991;  Jo  and 
Burden,  1992).  Finally,  at neuromuscular  synapses,  there 
is evidence  for the  existence  of a thrombin-like protease 
that  is  thought  to  mediate  synapse  elimination  in  an  in 
vitro system (Liu et al., 1994). 
Many examples now exist where a balance between pro- 
tease  and  protease  inhibitor  in  the  extracellular  matrix 
regulate developmental interactions between cells, includ- 
ing those for the  spread of tumors  (for review see Alex- 
ander  and  Werb,  1991).  Since  the  Neu  oncogene  is  ex- 
pressed  in  many  breast  and  ovarian  tumors  (Peles  and 
Yarden,  1993), ARIA-matrix interactions might also play 
a role in the spread of these tumors. 
While  we feel  that  this  mechanism  is  most  consistent 
with our data, we cannot rule out that there may be other 
mechansisms that regulate the release of ARIA at synap- 
tic junctions.  The intraceUular processing  and  release  of 
ARIA  from  its  membrane-spanning  precursor  protein, 
proARIA, and the possibility of juxtacrine interactions of 
proARIA with its receptor through cell-cell contact (Mas- 
sagud, 1990) offer additional ways that ARIA's  effects on 
postsynaptic cells may be regulated. 
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